可注射肽疗法:骨科与运动医学医师入门指南
本文为叙述性综述,通过PubMed检索评估可注射肽疗法(BPC-157、TB-4、TB-500、CJC-1295联合伊帕瑞林、替莫瑞林、GHK-Cu)的现有证据。多数证据来自临床前或动物研究,人体骨科数据缺乏,适应证、剂量、频率和疗程均未知,尚不能作出明确推荐。
要点
- BPC-157在肌腱和肌肉修复中显示潜在益处,但 largely 未在人体试验中验证。
- TB-4/TB-500在临床前模型促进血管生成和组织修复,但缺乏人体骨科数据,且为体育禁用物质。
- CJC-1295联合伊帕瑞林仅在糖皮质激素诱导肌流失的小鼠模型中显示改善最大强直张力。
核心结论
- 肽疗法可能具有显著的治疗和再生潜力,但骨科与运动医学医师必须理解目前缺乏支持这些肽临床使用的证据。
- 关于适应证、剂量、频率和治疗持续时间的信息仍然未知。
- 尽管这些肽在主流媒体和患者中流行,但在向患者作出明确推荐之前,仍需关于这些治疗方法安全性和有效性的重要研究。
研究设计与样本
- 叙述性综述,通过PubMed进行全面文献检索,以识别关于最流行的可注射肽疗法的生化和临床研究。
主要发现
- BPC-157在肌腱和肌肉修复中显示潜在益处,但这些发现 largely 未在人体试验中验证。
- 一项人体病例系列报告膝关节腔内注射BPC-157后疼痛改善,但显著的方法学缺陷和缺乏对照限制了其适用性和可靠性。
- TB-4及其衍生物TB-500在临床前模型中促进血管生成和组织修复,但缺乏人体骨科数据,且两者均为体育禁用物质。
- CJC-1295联合伊帕瑞林在糖皮质激素诱导肌肉流失的小鼠模型中显示最大强直张力显著改善,但这些发现仅限于动物研究。
- 替莫瑞林已获批用于治疗HIV相关脂肪营养不良,但无支持其用于骨科的证据。
临床怎么用
- 原文未据此给出推荐,仅指出骨科与运动医学医师应理解目前缺乏支持这些肽临床使用的证据,且适应证、剂量、频率和治疗持续时间仍未知。
局限性
- BPC-157的发现 largely 未在人体试验中验证。
- BPC-157的人体病例系列存在显著的方法学缺陷和缺乏对照,限制了其适用性和可靠性。
- TB-4和TB-500缺乏人体骨科数据。
- CJC-1295联合伊帕瑞林的发现仅限于动物研究。
- 替莫瑞林无支持其用于骨科的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides. PURPOSE: To evaluate the current evidence and applications of injectable peptide therapy, focusing on its potential in regenerative medicine and sports performance, to help orthopaedic providers better understand the current state of different therapeutic peptide approaches. STUDY DESIGN: Narrative review. METHODS: A comprehensive literature search was conducted using PubMed to identify biochemical and clinical studies on the most popular types of injectable peptide therapy. Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability. TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports. CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies. Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions. CONCLUSION: While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.
引用
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID: 41476424. doi:10.1177/03635465251357593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。